Post Hoc Subgroup Analyses of the Efficacy and Safety of Zavegepant for the Acute Treatment of Migraine According to Baseline Triptan Experience
Abstract
Introduction: Zavegepant is a small-molecule calcitonin gene-related peptide receptor blocker (gepant). Gepants may be particularly useful in people who are triptan insufficient responders (TIR) and/or have contraindications for use of triptans.
Methods: Post hoc analyses of efficacy and safety from the development program for zavegepant 10 mg nasal spray for the treatment of acute migraine in adults by baseline triptan experience. Pooled efficacy data from two double-blind, single-dose, randomized, placebo-controlled trials (NCT03872453, NCT04571060) were used to assess efficacy; co-primary efficacy endpoints were pain freedom (2 h PF) and most bothersome symptom (2 h MBS) freedom at 2 hours post-dose. Safety assessments included adverse events (AEs) from the 1-year, multiple-dose, open-label study (NCT04408794). Participants were grouped based on triptan use into a triptan naïve group (never used a triptan), TIR (used ≥1 triptans but not currently on a triptan), and current triptan users.
Results: Overall, 2061 (pooled efficacy analysis set) and 603 (long-term safety analysis set) participants were included. In pooled analyses, 2 h PF rates for zavegepant versus placebo were 21.0% versus 11.9% (p=0.0254) for current triptan users, 24.8% versus 17.4% (p=0.0029) for triptan-naïve, and 21.8% versus 12.6% (p=0.0024) for TIR. For 2 h MBS freedom, corresponding rates were 40.0% versus 29.5% (p=0.0440), 40.4% versus 34.0% (p=0.0303), and 41.0% versus 29.9% (p=0.0035). In…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.